Long-Term Liabilities: The sum of all non-current liabilities.
Lyell Immunopharma, Inc. (LYEL) had Long-Term Liabilities of $51.99M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$0.01M |
|
$-52.20M |
|
-- |
|
$0.01M |
|
$57.37M |
|
$-57.37M |
|
$5.17M |
|
$-52.20M |
|
$-52.20M |
|
$-52.20M |
|
$-52.20M |
|
$-52.20M |
|
$-52.20M |
|
$-57.37M |
|
$-55.65M |
|
14.75M |
|
14.75M |
|
$-3.60 |
|
$-3.60 |
|
| Balance Sheet Financials | |
$309.18M |
|
$44.20M |
|
$120.62M |
|
$429.80M |
|
$41.28M |
|
-- |
|
|
Long-Term Liabilities |
$51.99M |
$93.28M |
|
$336.52M |
|
$336.52M |
|
$336.52M |
|
14.76M |
|
| Cash Flow Statement Financials | |
$-54.74M |
|
$69.47M |
|
$0.00M |
|
$107.29M |
|
$122.02M |
|
$14.73M |
|
$6.02M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.49 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-819528.50% |
|
-819528.50% |
|
-- |
|
-745642.80% |
|
-745642.80% |
|
$-54.98M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-15.51% |
|
-15.51% |
|
-12.14% |
|
-15.51% |
|
$22.79 |
|
$-3.73 |
|
$-3.71 |
|